Loading...
Statistics

LYSOGENE - Biotechnology company in the field of gene therapy
www.lysogene.com/
Lysogene is a global leader in the research and clinical development of gene therapy for neurodegenerative disorders. Our mission is to radically improve ...

Lysogene.com

Lysogene.com report, domain review

Last update: 2017-04-28 12:30:53

Redirect checking

  • Domain isn't redirected.

Language

  • Declared Language code: Fr
  • Detected Language code: En

SSL checking

  • HTTPS: isn't used.

Social Shares

  • All Social Shares: 482
  • Facebook Shares: 434
  • LinkedIn Shares: 48

Content Report

  • Number of letters: 1519
  • Number of words: 265
  • Number of sentences: 9
  • Average words per sentences: 29
  • Number of syllables: 552
  • Syllables in words: 512
  • Average syllables in words: 2.08
  • Number of words in first three syllables: 97
  • Percentage of word / syllables: 36.60

Readability

  • Flesch–Kincaid Grade Level: 12.00
  • Flesch Reading Ease: 0.70
  • Coleman Liau Index: 12.00
  • Automated Readability Index (ARI): 12.00
  • Dale–Chall Readability: 10.00
  • SMOG Index: 12.00
  • Spache Readability: 5.00
  • Words not in Dale-Chall easy-word list: 170
  • Words not in Spache easy-word list: 130
Scores can be interpreted as shown in the table below:

Flesch–Kincaid Score | School Level

  • 90–100 | 5th grade: Very easy to read. Easily understood by an average 11-year-old student.
  • 80–89 | 6th grade: Easy to read. Conversational English for consumers.
  • 70–79 | 7th grade: Fairly easy to read.
  • 60–69 | 8th & 9th grade: Plain English. Easily understood by 13- to 15-year-old students.
  • 50–59 | 10th to 12th grade: Fairly difficult to read.
  • 30–49 | College: Difficult to read.
  • 0–30 | College graduate: Very difficult to read. Best understood by university graduates.

ARI: Score | Age

  • 1 | 5-6: Kindergarten
  • 2 | 6-7: First Grade
  • 3 | 7-8: Second Grade
  • 4 | 8-9: Third Grade
  • 5 | 9-10: Fourth Grade
  • 6 | 10-11: Fifth Grade
  • 7 | 11-12: Sixth Grade
  • 8 | 12-13: Seventh Grade
  • 9 | 13-14: Eighth Grade
  • 10 | 14-15: Ninth Grade
  • 11 | 15-16: Tenth Grade
  • 12 | 16-17: Eleventh grade
  • 13 | 17-18: Twelfth grade
  • 14 | 18-22: College

Dale–Chall Score: Easily understood by ...

  • 0.0 - 4.9: ... an average 4th-grade student or lower.
  • 5.0 – 5.9: ... an average 5th or 6th-grade student.
  • 6.0 – 6.9: ... an average 7th or 8th-grade student.
  • 7.0 – 7.9: ... an average 9th or 10th-grade student.
  • 8.0 – 8.9: ... an average 11th or 12th-grade student.
  • 9.0 – 10.0: ... an average 13th to 15th-grade (college) student.

Keywords (2 words) / counter

  • "mps iiia" / 5
  • "gene therapy" / 4
  • "i/ii clinical" / 2
  • "clinical trial" / 2
  • "trial gene" / 2
  • "iiia gangliosidosis" / 2
  • "phase ii/iii" / 2
  • "phase i/ii" / 2
  • "plans phase" / 2
  • "apr lysogene" / 2

Keywords (3 words) / counter

  • "clinical trial gene" / 2
  • "phase i/ii clinical" / 2
  • "mps iiia gangliosidosis" / 2
  • "trial gene therapy" / 2
  • "i/ii clinical trial" / 2

Important Meta Datas

  • Meta Title: LYSOGENE - Biotechnology company in the field of gene therapy
  • Meta description: Lysogene is a global leader in the research and clinical development of gene therapy for neurodegenerative disorders. Our mission is to radically improve the health of patients suffering from incurable life threatening conditions. We do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Other Meta datas:

  • Name: description
    Content: Lysogene is a global leader in the research and clinical development of gene therapy for neurodegenerative disorders. Our mission is to radically improve the health of patients suffering from incurable life threatening conditions. We do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.
  • Name:
    Content: text/html;charset=UTF-8
  • Name: viewport
    Content: width=1340

Html Elements

  • <div> : 55
  • <a> : 52
  • <li> : 31
  • <path> : 21
  • <title> : 14
  • <symbol> : 13
  • <p> : 12
  • <br> : 8
  • <svg> : 7
  • <span> : 7
  • <ul> : 7
  • <i> : 7
  • <use> : 6
  • <img> : 6
  • <script> : 5
  • <h2> : 5
  • <link> : 4
  • <meta> : 4
  • <header> : 3
  • <h3> : 2
  • <article> : 2
  • <footer> : 1
  • <head> : 1
  • <button> : 1
  • <defs> : 1
  • <hr> : 1
  • <html> : 1
  • <body> : 1
  • <nav> : 1
  • <form> : 1
  • <input> : 1

Html Classes

  • "nav-menu-item" : 21
  • "path1" : 13
  • "caret" : 7
  • "nav-item" : 7
  • "icon" : 6
  • "tile" : 6
  • "clearfix" : 5
  • "wrapper-content" : 5
  • "nav-menu-caret" : 5
  • "nav-menu" : 5
  • "nav-menu-content" : 5
  • "caret-down" : 5
  • "social-link" : 4
  • "path2" : 3
  • "text-content" : 3
  • "slider-item" : 3
  • "text-wrapper" : 3
  • "tweet-username" : 3
  • "tile-title" : 3
  • "post-info" : 2
  • "title-small" : 2
  • "title" : 2
  • "blogpost-content" : 2
  • "day" : 2
  • "icon-twitter" : 2
  • "tile-content" : 2
  • "path3" : 2
  • "blogpost-body" : 2
  • "hp-main--text" : 2
  • "hp-main--img" : 2
  • "clearifx" : 2
  • "month" : 2
  • "column" : 2
  • "blogpost" : 2
  • "mod-title" : 2
  • "icon-linkedin" : 1
  • "icon-facebook" : 1
  • "selected" : 1
  • "icon-youtube" : 1
  • "icon-contact" : 1
  • "logo" : 1
  • "email-link" : 1
  • "conf-msg" : 1
  • "footer-links" : 1
  • "path4" : 1
  • "path5" : 1
  • "path6" : 1
  • "page-hp" : 1
  • "header-top" : 1
  • "nobullets" : 1
  • "contact-link" : 1
  • "copyright" : 1
  • "slider-wrapper" : 1
  • "tile-link-news" : 1
  • "column-large" : 1
  • "column-right" : 1
  • "column-small" : 1
  • "column-left" : 1
  • "no-js" : 1
  • "module" : 1
  • "mod-hp-main" : 1
  • "wrapper-content_hp" : 1
  • "slider" : 1
  • "twitter-content" : 1
  • "hp-intro" : 1
  • "twitter-feed" : 1
  • "intro-2" : 1
  • "intro-1" : 1
  • "subfooter" : 1

Links

We found a total of 39 different links.
External dofollow links:
4
Internal dofollow links:
35

External dofollow

Number of External dofollow links: 4

  • Href: https://www.linkedin.com/company/lysogene
    Count: 1
  • Href: https://www.facebook.com/pages/LYSOGENE/161844883880252
    Count: 1
  • Href: https://twitter.com/LYSOGENE
    Count: 1
  • Href: https://www.youtube.com/user/LYSOGENEchannel
    Count: 1

Internal dofollow

Number of Internal dofollow links: 35

  • Href: http://www.lysogene.com/contact-us/
    Title: Contact us
    Count: 3
  • Href: http://www.lysogene.com/
    Title: EN
    Count: 1
  • Href: http://www.lysogene.com/fr/
    Title: FR
    Count: 1
  • Href: http://www.lysogene.com/about/our-history/
    Title: Aboutus
    Count: 2
  • Href: http://www.lysogene.com/about/expertise/
    Title: Expertise
    Count: 1
  • Href: http://www.lysogene.com/about/management-team/
    Title: Management
    Count: 1
  • Href: http://www.lysogene.com/about/board-of-directors/
    Title: Board of directors
    Count: 1
  • Href: http://www.lysogene.com/about/advisors/
    Title: Scientific advisors
    Count: 1
  • Href: http://www.lysogene.com/about/rare-diseases-policy/
    Title: Rare diseases policy
    Count: 1
  • Href: http://www.lysogene.com/about/transparency/
    Title: Transparency
    Count: 1
  • Href: http://www.lysogene.com/pioneering-science/concept/
    Title: PioneeringScience
    Count: 2
  • Href: http://www.lysogene.com/pioneering-science/pipeline/
    Title: Pipeline
    Count: 1
  • Href: http://www.lysogene.com/clinical-programs/
    Title: Clinicalprograms
    Count: 1
  • Href: http://www.lysogene.com/clinical-programs/mps-iiia-phase-i/
    Title: MPS IIIA
    Count: 1
  • Href: http://www.lysogene.com/clinical-programs/gm1-phase-i/
    Title: GM1 gangliosidosis
    Count: 1
  • Href: http://www.lysogene.com/patients-and-families/mps-iiia/
    Title: Patients andfamilies
    Count: 5
  • Href: http://www.lysogene.com/patients-and-families/gm1-gangliosidosis/
    Title: GM1 gangliosidosis
    Count: 4
  • Href: http://www.lysogene.com/patients-and-families/links-and-resources/
    Title: Links and resources
    Count: 1
  • Href: http://www.lysogene.com/partnering/
    Title: Partnering
    Count: 1
  • Href: http://www.lysogene.com/media-center/welcome/
    Title: Investors
    Count: 2
  • Href: http://www.lysogene.com/media-center/stock-information/
    Title: Stock Information
    Count: 1
  • Href: http://www.lysogene.com/media-center/news/
    Title: Press releases
    Count: 2
  • Href: http://www.lysogene.com/media-center/events/
    Title: Events
    Count: 1
  • Href: http://www.lysogene.com/media-center/financial-information/
    Title: AMF Regulated Information
    Count: 1
  • Href: http://www.lysogene.com/media-center/annual-general-assembly/
    Title: Annual General Assembly
    Count: 1
  • Href: http://www.lysogene.com/media-center/investor-contacts/
    Title: Investor Contacts
    Count: 1
  • Href: http://www.lysogene.com/in-the-media-3/
    Title: In the media
    Count: 1
  • Href: http://www.lysogene.com/media-center/news/lysogene-2016-annual-results/
    Title: Lysogene: 2016 annual results
    Count: 1
  • Href: http://www.lysogene.com/media-center/news/lysogene-announces-selection-of-mri-interventions-smartflow-cannula-for-phase-iiiii-clinical-study-in-mps-iiia/
    Title: Lysogene Announces Selection of MRI Interventions’ SmartFlow® Cannula for Phase II/III Clinical Study in MPS IIIA
    Count: 1
  • Href: https://twitter.com/#!/RoySocMed
    Title: @RoySocMed
    Count: 1
  • Href: https://twitter.com/#!/LYSOGENE
    Title: @LYSOGENE
    Count: 1
  • Href: https://twitter.com/#!/search/%23medinnov
    Title: #medinnov
    Count: 1
  • Href: https://twitter.com/#!/KarenAiach
    Title: @KarenAiach
    Count: 1
  • Href: http://www.lysogene.com/sitemap/
    Title: Sitemap
    Count: 1
  • Href: http://www.lysogene.com/terms-of-use/
    Title: Terms of use
    Count: 1